
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CV-01
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Angelini Pharma
Deal Size : $360.0 million
Deal Type : Licensing Agreement
Angelini Pharma Signs Option Agreement with Cureverse for Brain Health Asset
Details : Under the agreement, Angelini Pharma will lead all the development efforts for CV-01, a clinical Phase 1 investigational novel compound with broad potential to treat brain health diseases.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 21, 2024
Lead Product(s) : CV-01
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Angelini Pharma
Deal Size : $360.0 million
Deal Type : Licensing Agreement
